ORPEA

Earnings Release • Nov 9, 2010

FURTHER SOLID GROWTH IN Q3 2010: +12.8%

STRONG PROGRESS IN 9-MONTH SALES: +15.0% TO €714.2 MILLION

2010 AND 2011 GUIDANCE REAFFIRMED

Puteaux, 9th November 2010

ORPEA, a leading player in Long-Term Care (nursing homes), Post-Acute Care and Psychiatric Care, today announced its consolidated sales for the 3rd quarter ended 30th September 2010.

In €m IFRS	Quarterly			9 months
	Q3 2010	Q3 2009	Δ	2010	2009	Δ
France	214.8	190.1	+13.0%	628.1	542.7	+15.7%
% of total sales	87.9%	87.8%		87.9%	87.4%
International	29.5	26.5	+11.3%	86.2	78.3	+10.0%
% of total sales	12.1%	12.2%		12.1%	12.6%
Belgium	14.8	12.2		42.4	36.0
Spain	7.7	7.4		22.4	21.4
Italy*	4.4	4.4		13.1	13.7
Switzerland	2.6	2.6		8.3	7.4
Total sales	244.4	216.6	+12.8%	714.2	621.1	+15.0%
Organic growth			+8.1%			+8.9%

* Taking into account the divestment of a facility in Italy in 2009

Yves Le Masne, Deputy CEO, comments: "The Group's growth momentum continued over the 3rd quarter. This solid performance again reaffirms the relevance of ORPEA's development strategy, which is based on a combination of strong organic growth and controlled external growth.

The pace of organic growth, which remained buoyant over the quarter at +8.1%, should continue at a solid rate in 2011 with the opening of 5 major new clinics, 3 of them at the start of the year.

In the 2nd half, ORPEA focussed its development on the recently-announced major strategic acquisition of close to 5,000 beds. The finalising of this operation is taking place on schedule, and should be completed by the end of the year. This historic acquisition will represent a major additional external growth vector.

For the current financial year, ORPEA is particularly confident that it will achieve annual revenue of €960 million, along with solid profitability and an improvement in its debt ratios.

Lastly, ORPEA will possess the sector's largest growth reservoir consisting of over 9,500 beds being renovated or under construction, enabling it to confidently reaffirm its 2011 annual sales guidance of €1,210 million and to pursue its virtuous development in coming years, accompanied by further solid profitability and a continual increase in cash flow. "

Next press release: 2010 full-year sales Wednesday 16th February 2011 before market opening

About ORPEA (www.orpea.com): Listed on Euronext Paris since April 2002 and a member of the Deferred Settlement Service, ORPEA is a leading player in the Long-Term Care and Post-Acute Care sectors. At 1st January 2011, the Group will have a unique network of healthcare facilities with 32,939 beds (27,123 of which are operational) across 356 sites, including:

• 26,702 beds in France: 22,058 operational (including 3,052 being renovated) + 4,644 under construction, spread across 298 sites,
• 6,237 beds elsewhere in Europe (Spain, Belgium Italy and Switzerland): 5,065 operational (including 674 being renovated) + 1,172 under construction, spread across 58 sites.

Listed on Euronext Paris Compartment A of NYSE Euronext Member of the SBF 120 index and SRD ISIN: FR0000184798- Reuters: ORP.PA - Bloomberg: ORP FP

Investor Relations:

NewCap. ORPEA Emmanuel Huynh / Steve Grobet Yves Le Masne Tel: +33 (0)1 44 71 94 94 Deputy CEO orpea@newcap.fr Tel: +33 (0)1 47 75 78 07